文献速递心脑血管急症消化、代谢与肾脏急症

不同血压水平下降压药物治疗用于心血管病一级和二级预防:个体参与者数据荟萃分析

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
PubMed 文献 · Lancet · 2021-01-01
一句话结论收缩压每降低5 mm Hg,主要心血管事件风险约降低10%,无论既往有无心血管病,即使在正常或正常高值血压亦然。

该研究汇总48项随机试验、344 716例参与者的个体数据,比较降压药物与安慰剂或其他降压药、或强化与较弱降压方案,按基线收缩压7个分层(<120至≥170 mm Hg)分析。中位随访4.15年,12.3%发生至少一次主要心血管事件。无既往心血管病者收缩压每降5 mm Hg,主要心血管事件HR 0.91(95%CI 0.89-0.94);有既往心血管病者HR 0.89(95%CI 0.86-0.92)。分层分析未发现按基线心血管病状态或收缩压分层的疗效异质性可靠证据。作者认为固定幅度的药物降压对一级和二级预防同样有效,即使血压水平目前不被考虑治疗。

要点

  • 收缩压每降低5 mm Hg,无既往心血管病者主要心血管事件HR 0.91(95%CI 0.89-0.94),有既往心血管病者HR 0.89(95%CI 0.86-0.92)。
  • 无既往心血管病者主要心血管事件发生率:对照组31.9/1000人年(95%CI 31.3-32.5) vs 干预组25.9/1000人年(95%CI 25.4-26.4)。
  • 有既往心血管病者主要心血管事件发生率:对照组39.7/1000人年(95%CI 39.0-40.5) vs 干预组36.0/1000人年(95%CI 35.3-36.7)。
  • 基线收缩压<130 mm Hg者占有既往心血管病者19.8%(31 239例)、无既往心血管病者8.0%(14 928例),降压治疗在此血压范围仍显示获益。
  • 分层分析未发现按基线心血管病状态或收缩压分层(<120至≥170 mm Hg共7层)的疗效异质性可靠证据。

适用人群与场景

  • 48项随机试验的344 716例参与者,纳入有或无既往心血管病(随机化前报告卒中、心肌梗死或缺血性心脏病)者。
  • 排除:仅纳入心力衰竭患者的研究、急性心肌梗死或其他急性情况下短期干预的研究;每组随访需至少1000人年。

诊断标准与关键阈值

  • 主要心血管事件复合终点:致死性和非致死性卒中、致死或非致死性心肌梗死或缺血性心脏病、导致死亡或需住院的心力衰竭。
  • 按基线收缩压分为7个类别(<120至≥170 mm Hg)进行分层分析。

研究设计与关键结果

  • 研究类型:个体参与者数据荟萃分析,纳入48项随机试验(1972至2013年发表),共344 716例参与者。
  • 基线平均血压:有既往心血管病者146/84 mm Hg(n=157 728),无既往心血管病者157/89 mm Hg(n=186 988);基线收缩压<130 mm Hg者分别占19.8%(31 239例)和8.0%(14 928例)。
  • 中位随访4.15年(Q1-Q3 2.97-4.96),42 324例(12.3%)发生至少一次主要心血管事件。
  • 无既往心血管病者主要心血管事件发生率:对照组31.9/1000人年(95%CI 31.3-32.5) vs 干预组25.9/1000人年(95%CI 25.4-26.4)。
  • 有既往心血管病者主要心血管事件发生率:对照组39.7/1000人年(95%CI 39.0-40.5) vs 干预组36.0/1000人年(95%CI 35.3-36.7)。
  • 收缩压每降低5 mm Hg,主要心血管事件HR:无既往心血管病者0.91(95%CI 0.89-0.94),有既往心血管病者0.89(95%CI 0.86-0.92)。
  • 分层分析未发现按基线心血管病状态或收缩压类别分层的疗效异质性可靠证据。

证据类型、等级与局限

  • 证据类型:个体参与者数据荟萃分析(48项随机试验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为固定幅度的药物降压对主要心血管病的一级和二级预防同样有效,即使在目前不被考虑治疗的血压水平。
  • 作者建议医生与患者沟通降压治疗指征时,应强调降低心血管风险的重要性,而非仅关注血压下降本身。

指南或共识出处

  • Blood Pressure Lowering Treatment Trialists' Collaboration(牛津大学,英国牛津)汇总的48项随机试验个体数据,试验发表于1972至2013年。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure.

METHODS: We did a meta-analysis of individual participant-level data from 48 randomised trials of pharmacological blood pressure lowering medications versus placebo or other classes of blood pressure-lowering medications, or between more versus less intensive treatment regimens, which had at least 1000 persons-years of follow-up in each group. Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We pooled the data to investigate the stratified effects of blood pressure-lowering treatment in participants with and without prevalent cardiovascular disease (ie, any reports of stroke, myocardial infarction, or ischaemic heart disease before randomisation), overall and across seven systolic blood pressure categories (ranging from <120 to ≥170 mm Hg). The primary outcome was a major cardiovascular event (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring admission to hospital), analysed as per intention to treat.

FINDINGS: Data for 344 716 participants from 48 randomised clinical trials were available for this analysis. Pre-randomisation mean systolic/diastolic blood pressures were 146/84 mm Hg in participants with previous cardiovascular disease (n=157 728) and 157/89 mm Hg in participants without previous cardiovascular disease (n=186 988). There was substantial spread in participants' blood pressure at baseline, with 31 239 (19·8%) of participants with previous cardiovascular disease and 14 928 (8·0%) of individuals without previous cardiovascular disease having a systolic blood pressure of less than 130 mm Hg. The relative effects of blood pressure-lowering treatment were proportional to the intensity of systolic blood pressure reduction. After a median 4·15 years' follow-up (Q1-Q3 2·97-4·96), 42 324 participants (12·3%) had at least one major cardiovascular event. In participants without previous cardiovascular disease at baseline, the incidence rate for developing a major cardiovascular event per 1000 person-years was 31·9 (95% CI 31·3-32·5) in the comparator group and 25·9 (25·4-26·4) in the intervention group. In participants with previous cardiovascular disease at baseline, the corresponding rates were 39·7 (95% CI 39·0-40·5) and 36·0 (95% CI 35·3-36·7), in the comparator and intervention groups, respectively. Hazard ratios (HR) associated with a reduction of systolic blood pressure by 5 mm Hg for a major cardiovascular event were 0·91, 95% CI 0·89-0·94 for partipants without previous cardiovascular disease and 0·89, 0·86-0·92, for those with previous cardiovascular disease. In stratified analyses, there was no reliable evidence of heterogeneity of treatment effects on major cardiovascular events by baseline cardiovascular disease status or systolic blood pressure categories.

INTERPRETATION: In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high-normal blood pressure values. These findings suggest that a fixed degree of pharmacological blood pressure lowering is similarly effective for primary and secondary prevention of major cardiovascular disease, even at blood pressure levels currently not considered for treatment. Physicians communicating the indication for blood pressure lowering treatment to their patients should emphasise its importance on reducing cardiovascular risk rather than focusing on blood pressure reduction itself.

FUNDING: British Heart Foundation, UK National Institute for Health Research, and Oxford Martin School.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021. PMID: 33933205. doi:10.1016/S0140-6736(21)00590-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。